Loading stock…

Apollo Hospitals Enterprise Limited (APOLLOHOSP) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Apollo Hospitals Enterprise Limited

APOLLOHOSPMarket cap $12BPrice $79.6

Country🇮🇳India

SectorHealthcare

IndustryHealthcare Services

Runs India's largest private hospital network alongside pharmacies and diagnostics clinics, treating everything from cardiac surgery to cancer. Its 24/7 pharmacy delivery arm now reaches more customers than most of its hospitals combined, blending healthcare with retail scale.

In Bastion Portfolios?

52W Return-11%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+10%7

Revenue Forecast

Rev CAGR (1y)+14%7

Rev CAGR (3y)+16%8

Rev CAGR (5y)+12%8

Earnings Forecast

EPS Growth Y+1+22%8

EPS Growth Y+2+26%8

EPS Growth Y+3+22%8

Quality

Margins

EBIT Margin12%5

Net Income Margin8%5

Free Cash Flow Margin3%4

Debt

Net Debt/EBITDA1.75

Efficiency

ROE24%8

ROAna–

Earnings Stability77

GEAR+AVERAGE64

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)421

P/E Ratio (Forward 3y)292

P/BV11.81

EV Multiples

EV/EBITDA Fwd272

EV/EBIT Fwd332

Yield

Free Cash Flow Yield0.8%3

Dividend Yieldna–

Momentum

Short term

1 month return-11%2

3 month return-10%3

YTD return+12%7

Mid term

Price vs 52wHigh85%7

1 year return+3%5

Long term

3 year return+57%6

5 year return+82%7

Risk Shield

Price Risk

Beta0.48

Volatility19%10

Free Cash Flow

Free Cash Flow Margin3%4

Free Cash Flow Yield0.8%3

Quality

ROCE40%10

Earnings Stability77

Net Debt/EBITDA1.75

02Growth

Is it actually growing, and how fast?

APOLLOHOSPApollo Hospitals Enterprise

Revenue FY26$2.7B

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+14%7

Revenue, next 3Y, CAGR+16%8

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+22%8

EPS growth, FY28E+26%8

EPS growth, FY29E+22%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 16%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 10%/yr over the last 3 years and is set to grow 16%/yr from here.

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 22%/yr vs revenue 16%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

APOLLOHOSPApollo Hospitals Enterprise

Total return Current358%

Price return Current343%

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return-10%3

YTD return+12%7

MID & LONG-TERM▾SCORE

% of 52-week high85%7

1-year return+3%5

3-year return+57%6

5-year return+82%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +57% over three years and +82% over five, ahead of 60% of the market.

Strong recent results. The stock is outperforming so far this year (+12%).

WATCH

It's up 3% over the past year, but 15% below its 52-week high. That is a touch ahead of the market.

WEAKNESSES

The stock is underperforming over the past month (-11%) and over three months (-10%).

BOTTOM LINE

Long-Term Winner, Cooling Off

Multi-year returns are elite even though the latest weeks are quieter. Often a quality compounder taking a breather rather than breaking down. The one thing to watch: the stock is underperforming over the past month and over three months.

04Value

Are you paying a fair price for it?

Stop guessing on Apollo Hospitals Enterprise Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

APOLLOHOSPApollo Hospitals Enterprise

Revenue FY26$2.7B

GROWTH RATING↗

STRONG78 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+10%7

Revenue, next 1Y+14%7

Revenue, next 3Y, CAGR+16%8

Revenue, next 5Y, CAGR+12%8

EARNINGS FORECAST▾SCORE

EPS growth, FY27E+22%8

EPS growth, FY28E+26%8

EPS growth, FY29E+22%8

GROWTH ASSESSMENT

STRENGTHS

It out-grows 78% of companies worldwide.

Revenue grew 10%/yr over the last 3 years, ahead of 60% of companies worldwide.7/10

Revenue is set to grow 16%/yr over the next 3 years, ahead of most of the market.8/10

Revenue grew 10%/yr over the last 3 years and is set to grow 16%/yr from here.

The runway holds up: revenue is set to grow 12%/yr over five years.8/10

Earnings are set to grow faster than sales (EPS about 22%/yr vs revenue 16%/yr), so margins should widen.

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Hyper Compounder

A top-tier grower that's speeding up.

03Price Momentum

Is the market behind it right now?

APOLLOHOSPApollo Hospitals Enterprise

Total return Current358%

Price return Current343%

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-11%2

3-month return-10%3

YTD return+12%7

MID & LONG-TERM▾SCORE

% of 52-week high85%7

1-year return+3%5

3-year return+57%6

5-year return+82%7

MOMENTUM ASSESSMENT

STRENGTHS

Strong long-term results. Long-term holders have seen +57% over three years and +82% over five, ahead of 60% of the market.

Strong recent results. The stock is outperforming so far this year (+12%).

WATCH

It's up 3% over the past year, but 15% below its 52-week high. That is a touch ahead of the market.

WEAKNESSES

The stock is underperforming over the past month (-11%) and over three months (-10%).

BOTTOM LINE

Long-Term Winner, Cooling Off

04Value

Are you paying a fair price for it?

Stop guessing on Apollo Hospitals Enterprise Limited. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community